Biogen (BIIB) Stock Upgrade: Target Raised to $225 from UBS
Published on 4/22/2026
AI Summary
UBS has upgraded Biogen (BIIB) stock, citing favorable pipeline catalysts as a key reason. The target price for Biogen shares has been raised to $225. This adjustment reflects confidence in the company's growth potential and anticipated drug approvals. The upgrade may positively influence market perception and investor interest in Biogen moving forward.
